Biofrontera Inc
NASDAQ:BFRI

Watchlist Manager
Biofrontera Inc Logo
Biofrontera Inc
NASDAQ:BFRI
Watchlist
Price: 0.8326 USD -0.29% Market Closed
Market Cap: 9.7m USD

Operating Margin
Biofrontera Inc

-47.4%
Current
-58%
Average
5.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-47.4%
=
Operating Profit
-17.6m
/
Revenue
37.2m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Biofrontera Inc
NASDAQ:BFRI
9.7m USD
-47%
US
Eli Lilly and Co
NYSE:LLY
982.2B USD
44%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
US
Johnson & Johnson
NYSE:JNJ
526.1B USD
27%
CH
Roche Holding AG
SIX:ROG
277.8B CHF
34%
UK
AstraZeneca PLC
LSE:AZN
217.9B GBP
24%
CH
Novartis AG
SIX:NOVN
221.8B CHF
33%
US
Merck & Co Inc
NYSE:MRK
270.7B USD
38%
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
42%
IE
Endo International PLC
LSE:0Y5F
213.9B USD
11%
US
Pfizer Inc
NYSE:PFE
145.8B USD
29%
No Stocks Found

Biofrontera Inc
Glance View

Market Cap
9.7m USD
Industry
Pharmaceuticals

Biofrontera, Inc. is a biopharmaceutical company, which engages in the commercialization of pharmaceutical products. The company is headquartered in Woburn, Massachusetts and currently employs 69 full-time employees. The company went IPO on 2021-10-14. The firm is specialized in the commercialization of pharmaceutical products for the treatment of dermatological conditions for the diseases caused primarily by exposure to sunlight that result in sun damage to the skin. Its products focus on the treatment of actinic keratoses, which are skin lesions that lead to skin cancer. The company also markets a topical antibiotic for treatment of impetigo, a bacterial skin infection. The Company’s principal product is Ameluz, which is a prescription drug for use in combination with its medical device, the BF-RhodoLED lamp, for photodynamic therapy (PDT) in the United States for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company offers Xepi for the treatment of impetigo, a common skin infection, due to Staphylococcus aureus or streptococcus pyogenes.

BFRI Intrinsic Value
HIDDEN
Show
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-47.4%
=
Operating Profit
-17.6m
/
Revenue
37.2m
What is the Operating Margin of Biofrontera Inc?

Based on Biofrontera Inc's most recent financial statements, the company has Operating Margin of -47.4%.

Back to Top